Deep vein thrombosis as the first presentation of diabetic ketoacidosis

authors:

avatar Mohsen shafiepour , avatar Majid Golestani Eraghi , avatar Mohammadreza Shafiepour , avatar Mehrdad Vahedian , avatar Mehrdad Farokhnia , avatar Masoumeh Hoseini Askarabadi , *

Koomesh: Vol.21, issue 2; 391-393
published online: June 01, 2019
article type: Research Article
received: July 01, 2018
accepted: October 01, 2018

how to cite: shafiepour M, Golestani Eraghi M, Shafiepour M, Vahedian M, Farokhnia M, et al. Deep vein thrombosis as the first presentation of diabetic ketoacidosis. koomesh. 2019;21(2):e153084. 

Abstract

Deep vein thrombosis (DVT) as a manifestation of vein thromboembolism is a frequent and potentially life-threatening disease especially in hospitalized and immobile patients. Diabetes mellitus and diabetic ketoacidosis (DKA) are of its reported, challenging risk factors. Here, we reported a diabetic patient presented with DKA and DVT who showed hypothyroidism-induced warfarin resistance

References

  • 1.

    Samama M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. the sirius study. Arch Intern Med 2000; 160: 3415-3420.

  • 2.

    Russell MW, Taylor DC, Cummins G, Huse DM. Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients. Am J Manag Care 2002; 8: S3-9.

  • 3.

    Chung WS, Lin CL, Kao CH. Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study. Thromb Haemost 2015; 114: 812-818.

  • 4.

    Burzynski J. DKA and thrombosis. CMAJ 2005; 173: 132-133.

  • 5.

    Deep venous thrombosis (DVT). http://emedicine.medscape.com/article/1911303-overview#a6. Last updated Jul 06, 2017.

  • 6.

    Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005; 48: 1017-1021.

  • 7.

    Zhang Y, Shi Y, Ye R, Shao N, Pan F, Lin Y, et al. Diabetes mellitus-associated hyperglycemia is a risk factor for recurring deep vein thrombosis and post-thrombotic syndrome-a cohort study. Int J Clin Exp Med 2016; 9: 17739-17749.

  • 8.

    Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 2002; 51: 471-476.

  • 9.

    Murakami H, Okazaki M, Amagasa H, Oguchi K. Increase in hepatic mRNA expres-sion of coagulant factors in type 2 diabetic model mice. Thromb Res 2003; 111: 81-87.

  • 10.

    Heit JA, Leibson CL, Ashrani AA, Petterson TM, Bailey KR, Melton LJ. Is diabetes mellitus an independent risk factor for venous thromboembolism? a population-based case-control study. Arterioscler Thromb Vasc Biol 2009; 29: 1399-1495.

  • 11.

    Ho J, Pacaud D, Hill MD, Ross C, Hamiwka L, Mah JK. Diabetic ketoacidosis and pediatric stroke. CMAJ 2005; 172: 327-328.

  • 12.

    Osinbowale O, Al Malki M, Schade A, Bartholomew JR. An algorithm for managing warfarin resistance. Cleve Clin J Med 2009; 76: 724-730.

  • 13.

    Sandards of medical care in diabetes 2017. care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.../DC_40_S1_final.pdf.

  • 14.

    Tomisti L, Del Re M, Bartalena L, Tanda M, Pucci A, Pambianco F, et al. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. Endocr Pract 2013; 19: 1043-1049##.